"Soluble" (K F eHI[Fen(C N )6]) and "insoluble Prussian blue" (FeI1,4[Fe,I(C N )6]3 labelled with 59Fe either in the ferric (Fe1 1 1 ) or ferro (Fe1 1 ) position and 14C in the cyanide group were synthe sized and administered intraperitoneally or orally to adult female rats with normal body iron stores.
Introduction
Prussian blue derivatives ("soluble", KFein[Fen(CN)6]; "insoluble", FeIII4[FeII(CN)6]3) adsorb caesium or thallium selectively even in so dium or potassium rich milieu [1] [2] , The efficacy of hexacyanoferrate(II) compounds as scavenging agents for radiocaesium isotopes has been used for their separation from nuclear fission products and dilute solutions [3] [4] , Furthermore, hexacyanoferrates(II) have been used for preventing the in testinal absorption [5] [6] and the decorporation of already absorbed radiocaesium in animals [7] [8] and man [9] [10] .
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Verlag der Zeitschrift für Naturforschung, D-7400 Tübingen 0341-0382/90/0600-0681 $01.30/0 Following the nuclear reactor catastrophe in Chernobyl in April 1986, which resulted in an Europe wide contamination of the food chain with the potential hazardous radionuclides 134Cs and I37Cs, the efficacy of practical procedures for the prevention of radiocaesium incorporation from contaminated diets was reinvestigated and im proved [11] [12] [13] [14] , Empirically, no toxic side effects, affecting health and development of animals were observed after application of even large dosages of hexacyanoferrates(II), i.e. 2% KFe[Fe(CN)6] in drink ing water for a 12 weeks period in rats [15] and 5-10 g N H 4Fe[Fe(CN)6] for 15 d in sheep [12] , From these studies, a complete non-absorption of soluble and insoluble Prussian blue in the intesti nal tract after oral application was assumed and appropriate pharmaceutical preparations were authorized as antidotes against (radio)caesium and thallium intoxications for example in WestGermany (i.e. "Radiogardase-Cs", Heyl, Berlin, F.R.G.).
However, prior to the widespread use of hexacyanoferrates(II) in the case of Chernobyl-like sev ere nuclear accidents in the future, the limited bioavailability of iron and esp. of the C N -group should be demonstrated also by experimental in vestigations. The absorption of ferrous and ferric iron from Prussian blue was shown to be small in rats [15] and piglets [14] . In the present study, var ious 59Fe and 14C labelled hexacyanoferrate(II) compounds with high purity were synthesized and administered orally or parenterally to rats. Be cause of the high specific activities used and the low body weight of rats as compared to cows or piglets, the absorption, distribution and excretion of even small amounts of 59Fe and ,4C could be studied with more precision than in earlier studies.
Materials and Methods
All chemicals used were of analytical grade and obtained from E. Merck, Darmstadt. K 14CN (37 MBq (1 mCi)/1.19 mg) and 59FeCl3 (37 MBq (1 mCi)/184 ng) were obtained from Amersham International, England. 59Fe(III) in acid solution was reduced to 59Fe(II) by the addition of a 10-fold molar excess of ascorbic acid.
Synthesis o f ,4C a n d 59Fe labelled hexacyanoferrates ( I I )
To a solution of 139 mg (0.5 mmol) FeS04-7 H 20 in 20 ml of water were added 14.8 MBq (400 |iCi) 59Fe(II) in 0.05 m hy drochloric acid. After stirring under N 2-atmosphere for 15 min, a solution of 260 mg (4 mmol) potassium cyanide (37 MBq, 1 mCi 14C) in 10 ml H 20 was slowly added. The alkaline reaction mix ture was kept under reflux for 15 min. After cool ing to room temperature, the mixture was filtered. The clear filtrate was acidified by the addition of 1 m HC1 and evaporated to dryness under reduced pressure. The yellow residue was resolved in 5 ml of water and precipitated by adding an equal vol ume of ethanol. After centrifugation at 3000 g for 30 min, the supernatant was discharged and the pellet was lyophilized. Yield, 173 mg (82%); spec. For determination of iron in the hexacyanoferrates(II), the solid samples were treated with boil ing concentrated H 2S 0 4. The iron sulfate formed was dissolved in 0.1 m HC1 and iron was deter mined spectrophotometrically using bathophenanthrolin as color reagent.
A n im a l e x p e rim e n ts a n d sa m p le w orku p Female Wistar rats (250-280 g; Wiga, Hanno ver, F.R.G.), kept on a standard food in pellet form (Altromin 1328; iron content, 250 mg/kg; Altromin, Lage, F.R.G.) and tap water ad libitum were used. Due to the high iron content of the diet, the liver iron concentration was slightly increased (0.4-0.5 mg Fe/g liver wet weight). The rats were fasted 24 h before and 4 h after the respective administration of labelled hexacyanoferrates(II). Aqueous solutions or suspensions of HCF (10-13 mg, 0.96-1.70 MBq (26-46 (aCi) 59Fe and 1.22-2.89 MBq (33-78 fiCi) ,4C) were adminis tered by intraperitoneal injection or gastric in tubation. After administration of hexacyanoferrates(II) the rats were kept in individual meta bolic cages over 7 days for a quantitative collection of urine and faeces.
The whole body retention of injected or ab sorbed oral 59Fe was measured 7 days after appli cation in the center of a 200 cm long 4 Tt-geometry whole body radioactivity detector with liquid or ganic scintillator in the energy range from 980-3000 keV as described for humans [16] . The ex pired air of the rats was measured for 14CO :-radioactivity during the first 24 h after i.p. and oral application of l4C-labelled hexacyanoferrates(II) in a modified 14C 0 2 respiration analyzer type FHT 50 A (Frieseke and Hopfner, Erlangen, F.R.G.). The detection limit was 0.01% of the administered l4C-activity. Within each experiment, the noise lev el of the system was controlled for exterior radia tion effects (59Fe in rats) by disconnecting the air flow between the metabolic cage and the 14C 0 2-flow through methane proportional detector for a 60 min period (Fig. 1) .
The rats were sacrificed by exsanguination from the abdominal aorta while under light ether nar cosis. The theoretical blood volume was calculated as 5.6% of the body weight, the specific weight of blood as 1.054 g/ml [17] . Blood, liver, spleen, kid neys, heart/lung and gut were removed and the 59Fe-content of organs and carcass measured with in the whole body radioactivity detector. For 14C-estimation, organs were dried by lyophilization and portions of 0.5 g each converted to I4C 0 2 us ing a sample oxidizer (Tri-Carb model 306, Carbosorb C 0 2-absorber, Packard-Instrument Co.). The l4C-activity was measured by liquid scintillation counting using a permafluor premix cocktail and a TriCarb Model 4430 liquid scintillation spectro meter.
Results
"Soluble" (KFe[Fe(CN)6) and "insoluble" (Fe4[Fc(CN)6]3) "Prussian Blue" labelled with 59Fe in the ferric or ferrous position and 14C in the cya nide group were synthesized and used for the esti mation of their bioavailability in rats. 59FeCl3 and K 4[59Fe(,4CN)6] were used as reference com pounds.
B io a v a ila b ility o f f e r r ic iron f r o m h e x a c y a n o fe r ra te s (II)
Ferric chloride. After o r a l a d m in istra tio n of a tracer dose of [59Fe]ferric chloride, about 8% of the dose was absorbed. This iron was incorporated into the hemoglobin of circulating erythrocytes or retained in carcass and liver, whereas the urine ex cretion was negligible (Tables I and II) .
. Following the i.p. in jection of a 10 mg amount (1.6 mg ferric iron), the ferric iron was almost completely retained after 7 days (96.2% whole-body-retention, Table I ). The organ distribution is similar to that found after oral ad ministration of 59FeCl3, except that a large fraction (38%) of the f e r r ic iron was associated with the gut (Table II) . On the first look, this might indicate that a significant portion of the colloid-soluble hexacyanoferrate(II) complex had reacted with the tissue, became insoluble and metabolically inert. However, considering the high urine excretion of 14C from this experiment and the respective 59'Feand 14C-data from the analogous experiment using KFe[59Fe(14CN )6], this non-metabolized fraction of KFe[Fe(CN)6] is much smaller (about 10-15%).
The o ra l a d m in is tra tio n of a single or five sub sequent daily doses of K 59Fe[Fe(14CN)6] (10 mg each, 1.6 mg ferric iron), resulted in a ferric iron absorption of 0.7 ± 0.3% (= 59Fe-WBR). The dis tribution of iron in blood and various organs was found to be similar to that of Fe(III) from ferric chloride (Table II) .
59Fe4[Fe(14CN )6]3. The absorption and organ distribution of labelled ferric iron was similar to that of Fe(III) from K 59Fe[Fe(14CN)6] and 59FeCl3 (Tables I and II) . 86.1 ± 1 1.6 1 59Fe-activity in 6-10 ml of blood, recovered from punction o f the aorta abdominalis (incomplete whole body blood volume; = 14.8 ml theoretical blood volume for 265 g body weight).
2 Oral applications (10 mg each) on 5 subsequent days.
Bioavailability offerrous iron from hexacyanoferrates ( I I )
K 4[59Fe(14CN)6]. Potassium hexacyanoferrate(II) (10 mg) was taken as reference for the bioavailabil ity of hexacyanoferrate(II) anion.
Following parenteral administration, the 59Fe-whole body retention from potassium hexacyanoferrate(II) was only small and 99% of the 59Fe and 14C dose were found in the urine within 7 days (Ta ble I). The distribution of the retained 59Fe-labelled ferrous iron in blood and organs was found m arkedly different from oral ferric iron (Table II) . M ost o f 59Fe-label was found in carcass and kid neys, and only small amounts of the ferrous iron in liver and blood (Table II) . After oral administra tion, 2.6% of 59Fe(II) were absorbed, but again, only a minor fraction of absorbed iron was re tained in the whole body (0.09% of dose, Table I ). The organ distribution of 59Fe was very similar to th at found after i.p. injection, except showing more 59Fe-activity in the blood after oral applica tion.
K Fe[59Fe(14CN)6], The i.p. injection resulted in a 8.6% 59Fe-whole body retention after 7 days, whereas 87.2% o f the ferrous iron and 88.5% 14C were found in the urine (Table I ). Similar to K 4[59F e (14CN)6] , the 59Fe-activity in blood was very low, and the retained 59Fe was found mainly in the carcass, liver, kidney and gut (Table II) .
After oral administration, the whole-body-retention of ferrous iron was extremely low (0.03% of the dose). As indicated by the erythrocyte incorpo ration (Table I) , more iron was found in the blood as com pared to i.p. application (El in % of WBR = 38% vs. 1.1%).
Fe4[59F e(14CN )6]3. Again, the absorption and retention of labelled ferrous iron was extremely small (0.01%) and similar to that of Fe(II) from KFe[59Fe(CN)6] (Tables I and II) .
Bioavailability o f cyanide from ,4C-labelled hexacyanoferrates (II)
The 14C-activities found in rat organs were small in general (< 1 % o f dose), but much higher after parenteral adm inistration of [14C]hexacyanoferrates(II) as com pared to oral adm inistration (< 0.01% ; Table III) . Table III . 59Fe-and l4C-activity in organs of rats (n = 2 -5 ), 7-10 days after i.p. injection and oral adm inistration of 59FeC l3 (tracer dose) and 59Fe and l4C labelled hexacyanoferrates(II) (10 mg) (in % of administered dose).
Compound
Rats n Table IV . 59F e/14C-ratio (mean ± SD) in blood and organs o f rats (n = 3 -5 ) 7 -10 days after adm in istration of 10 mg of 59Fe and 14C labelled hexacyanoferrates(II). With respect to the expired l4C 0 2-activity there was found a difference between parenteral and oral application of [14C]hexacyanoferrates(II) (Ta ble V). Following i.p. injection, the signals meas ured were within the noise level (< 0.01 % of dose), whereas after oral application, a small but signifi cant fraction of expired 14C 0 2 (-0.1% of dose) was measured. A typical l4C 0 2-expiration profile Table V from a rat given K 59Fe[Fe(14CN)] in aqueous solu tion through a gastric tube is shown in Fig. 1 , 0.06% of the 14C-activity of ,4C 0 2 were detected in the breath within 24 h after application.
Discussion
The efficacy of iron(III) hexacyanoferrate(II) for the prevention of intestinal radiocaesium up take or decorporation in animals and humans is well established [5, 7, 9] . However, up to now, very limited information concerning the bioavailabili ty of iron and cyanide from these compounds is available.
Regarding the bioavailability of iron and cya nide after oral administration of hexacyanoferrates(II), the dissociation and the purity of the re spective preparation have to be considered: a)
In the aqueous milieu of the intestinal tract the dissociation of hexacyanoferrates(II) can be described by a two step reaction: Time (hours) As a consequence of reaction 1 and 2, ferric and ferrous iron as well as cyanide are released from the finely dispersed hexacyanoferrate(II) com pounds prior to intestinal absorption. From the chemistry of transition metal hexacyanoferates(II) it is known that, despite low pH values, these com plexes are rather stable in aqueous solution (K d reac.2 = 10-35 mol/1, [18] ). However, after oral application the influence of gastric and duodenal juice, bile and colon bacteria have to be consid ered, which may result in the release of significant amounts of iron and cyanide.
b) The hexacyanoferrate(II) anion ([Fe(CN)6]4~), as formed in reaction 1, can be hydrolyzed to fer rous iron and cyanide according to reaction 2 be fore and after intestinal absorption. c) Crude (non-dialyzed) preparations of colloi dal hexacyanoferrate(II) may contain large amounts of by-products ([Fe(CN)6]4", FeCl3, KC1 etc.) which may serve in part as the real origin of absorbed iron and cyanide. In addition, significant amounts of anions (e.g. cyanide) can be adsorbed on the colloidal hexacyanoferrate(II) complex dur ing preparation and it was suggested, that most of the bioavailable cyanide may be derived from this adsorbed cyanide fraction [19] ,
Metabolism o f iron and cyanide in rats after intraperi toneal application o f hexacyanoferrates ( I I )
From the experiment with i.p. injection of K 59Fe[Fe(14CN)6] and KFe[59Fe(14CN)6] an almost complete in vivo dissociation of the colloidal hexacyanoferrate(II) complex according to reaction (1) can be concluded, since the urine excretion of cyanide as well as ferrous iron (probably non-dissociated [Fe(CN)6]4-) was 84-88% and the ferric iron was retained in the body almost quantitative ly. This is in good agreement with earlier results from Dvorak et al. [15] , who calculated an in vivo dissociation of the complex of about 60%. Con cerning the stability of these compounds over a wide pH-range in vitro, this result may surprise. However, the equilibrium (reaction (1)) is proba bly shifted to the right by the reaction of apotransferrin with Fe3+ and the fast excretion of [Fe(CN)6]4" through the kidney.
The ferric iron was almost completely retained in the body (probably used for haemoprotein bio synthesis and incorporated into the body iron stores). For labelled ferric iron, the 59Fe/14C-ratio in rat organs (Table IV) was much higher than 1.0 (about 20 in liver and spleen and about 400 in blood), indicating that the ferric iron was mainly accumulated in the blood.
About 90% of the 59Fe and l4C from the i.p. in jected KFe[59Fe(14CN)6] were excreted with the urine within 7 days. An additional fraction (3% 59Fe) was found in the faeces (bile excretion ?).The 59Fe/,4C-ratios of rat organs were close to 1.0 (Table IV) , indicating that the retained ferrous iron is distributed together with cyanide, probably as non-dissociated [Fe(CN)6]4~. Free ferrous iron, as product of reaction (2), is not stable under in vivo condition. After oxidation, most of this iron should be bound to apotransferrin and used in the erythropoesis or stored in ferritin. The 59Fe/,4C-ratio (between 1.0 and 1.7 in organs and 1.9-6.0 in blood) demonstrates that after i.p. administration of K 4[59Fe(CN)6] and KFe[59Fe(CN)6] respectively (Table III) , only small fractions of the [Fe(CN)6]4~ anion are dissociated in vivo according to reaction (2) . This can also be concluded from the results, that no 14C 0 2 was detectable in the expired air of rats, receiving ,4C-labelled soluble Prussian blue by i.p. injection.
Absorption and metabolism o f iron and cyanide in rats after oral application o f hexacyanoferrates ( I I )
The very low bioavailability of the ferric iron (0.3-0.7% W BR, Table I ) from "soluble" and "insoluble" Prussian blue corresponds to the well known poor iron absorption of trivalent iron con taining inorganic and organic iron complexes in man [20] , although rats are capable of synthesizing ascorbic acid and to reduce non available trivalent to absorbable bivalent iron at least to a certain de gree.
About 2.6% of the ferrous iron from K 4[Fe(CN)6] (10 mg dose) were absorbed (wholebody-retention and urine activity), most of it (2.5%) excreted by the kidneys (Table I ). This is in full agreement with results of Dvorak et al. [15] , who described an absorption (urine excretion and organ activities) of 2.1%, independent of the oral dose (0.5-50 mg K 4[Fe(CN)6]). The even lower bioavailability of the ferrous iron from both ferric hexacyanoferrates(II) (0.01-0.03% WBR, (Fig. 2) .
The erythrocyte incorporation (Table I ) from the experiment with KFe[59Fe(14CN )6] and K 4[59Fe(14CN)6] are significantly higher after oral administration as compared to the experiment with i.p. injection. This difference must be inter preted as intestinal hydrolysis reaction of [Fe(CN)6]4" according to reaction (2), followed by the independent absorption of ferrous iron and cyanide. The absorption of the small fraction of free cyanide account for the detectable ,4C 0 2-activity in the expired air of rats after oral adminis tration of 14C-labelled hexacyanoferrates(II).
Bioavailability o f cyanide from oral hexacyanoferrates ( I I )
Regarding the high cyanide content of hexacyanoferrate(II) compounds, the potential toxicity of oral hexacyanoferrates(II) should mainly de pend on the amount of non-complex-bound "free" cyanide in the body (see reaction (2)). Very small but still measurable amounts of cyanide and iron are absorbed and metabolized in rats from differ ent hexacyanoferrates(II) after oral administration (Table I, Table III ). From a 10 mg dose only about 0.04-0.08% of the 14C-activity were exhaled as l4C 0 2 within 24 h after application (Table V, Fig. 1 ). In the urine, collected for 7 days after oral application of [59Fe]ferrous iron and 14C-labelled hexacyanoferrates(II), the 14C-activity was signifi cantly higher than the 59Fe-activity, indicating that a substantial fraction of the cyanide was not bound to iron as [Fe(CN)6]4~, but excreted after re lease from the hexacyanoferrate(II) anion proba bly as C N ' or SCN". A schematic summary of the absorption and ex cretion of iron and cyanide from oral hexacyanoferrates(II) is shown in Fig. 2 .
Assuming that about 1/3 of the absorbed "free" cyanide is exhaled as C 0 2 and HCN, and 2/3 are excreted in the urine mainly as rhodanide [21] , then, after oral administration of 36 mg hexacyanoferrate(II)/kg body weight in rats, about 16-60 |ig free cyanide/kg body weight is absorbed from a single dose of hexacyanoferrate(II) in maxi mum (Table VI) .
As these roughly estimated values are about 70-270 times below the lethal dose of 4.3 mg C N -/kg body weight in rats [22] , no cyanide intox ication after single doses up to 100 mg/kg of hexacyanoferrates(II) have to be expected. Because of the fast detoxification rate of cyanide, e.g. 2.4 mg CN/kg/h in guinea-pigs [23] , a toxic effect due to chronic cyanide poisoning after prolonged oral ap plication of hexacyanoferrates(II) is also improba ble.
In conclusion, the bioavailability of iron and cyanide from oral administered purified hexacyanoferrates(II) was found to be very low in rats. Since oral Prussian blue treatment has been done already in humans in the case of accidental radio caesium contaminations and in thallium intoxi cations [24] , a low bioavailability of cyanide from hexacyanoferrate(II) is very likely in humans, too. However, prior to a widespread use of these com pounds in humans the transcription of the results in rats to human conditions has to be demonstrat ed. In addition, it is necessary to establish detailed specifications for the purity and the caesium bind ing capacities of the technically produced hexacyanoferrates(II). With regard to a long-time treatment with oral Prussian blue, further studies in domestic animals are needed.
